Jafron BiomedicalLtd First Quarter 2024 Earnings EPS CN0.35 - Simply Wall St
| 300529 Stock | 30.48 0.41 1.36% |
About 54% of Jafron Biomedical's investors are presently thinking to get in. The analysis of overall sentiment of trading Jafron Biomedical Co stock suggests that some investors are interested at this time. The current market sentiment, together with Jafron Biomedical's historical and current headlines, can help investors time the market. In addition, many technical investors use Jafron Biomedical stock news signals to limit their universe of possible portfolio assets.
Jafron |
Jafron BiomedicalLtd First Quarter 2024 Earnings EPS CN0.35 Simply Wall St
Read at news.google.com
 |
Jafron Biomedical Fundamental Analysis
We analyze Jafron Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jafron Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jafron Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Jafron Biomedical is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Jafron Biomedical Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Jafron Biomedical stock to make a market-neutral strategy. Peer analysis of Jafron Biomedical could also be used in its relative valuation, which is a method of valuing Jafron Biomedical by comparing valuation metrics with similar companies.
Peers
Jafron Biomedical Related Equities
| 000995 | Gansu Huangtai | 2.96 | ||||
| 688137 | Suzhou Novoprotein | 2.37 | ||||
| 600223 | Lushang Property | 1.85 | ||||
| 300841 | Chengdu Kanghua | 1.73 | ||||
| 300364 | COL Digital | 1.54 | ||||
| 603392 | Beijing Wantai | 1.28 | ||||
| 001299 | Shaanxi Meineng | 1.36 | ||||
| 605168 | Threes Company | 1.44 | ||||
| 601600 | Aluminum Corp | 1.57 |
Complementary Tools for Jafron Stock analysis
When running Jafron Biomedical's price analysis, check to measure Jafron Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jafron Biomedical is operating at the current time. Most of Jafron Biomedical's value examination focuses on studying past and present price action to predict the probability of Jafron Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jafron Biomedical's price. Additionally, you may evaluate how the addition of Jafron Biomedical to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |